Please wait while the formulary information is being retrieved.
SHINGRIX (VARICELLA-ZOSTER VIRUS GLYCOPROTEIN E,REC/AS01B ADJUVANT/PF)
- Prevention of herpes zoster
(PF) 50 mcg/0.5 mL intramuscular suspension, kit
- Inject 0.5 milliliter (50 mcg) by intramuscular route once
Prevention of herpes zoster
- Inject 0.5 milliliter (50 mcg) by intramuscular route once
- Inject 0.5 milliliter (50 mcg) by intramuscular route once repeat 0.5Ml dose 2 to 6 months after the first dose (total of 2 doses)
- None
Contraindicated
- fingolimod
- Gilenya
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- No disease contraindications
SHINGRIX (VARICELLA-ZOSTER VIRUS GLYCOPROTEIN E,REC/AS01B ADJUVANT/PF)
- Prevention of herpes zoster
- None
- Chills
- Erythema
- Fatigue
- Fever
- Gastrointestinal irritation
- Headache disorder
- Injection site sequelae
- Localized edema
More Frequent
Severe
Less Severe
- None
- Acute abdominal pain
- Arthralgias
- Diarrhea
- Dizziness
- Malaise
- Myalgias
- Nausea
- Pruritus of skin
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Optic neuropathy
Less Severe
- Lymphadenopathy
Contraindicated
None
Severe Precaution
Varicella Vacc. recomb (Zoster)
Not to be used for prevention of primary varicella infection (chickenpox) and not indicated in pediatrics.
- 1 Day – 18 Years
- Not to be used for prevention of primary varicella infection (chickenpox) and not indicated in pediatrics.
Management or Monitoring Precaution
None
Zoster Vaccine Recombinant
- Severity Level:
2
- Additional Notes: Insuff human data; animal data sug no known dev tox
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Zoster Vaccine Recombinant
None
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Prevention of herpes zoster | |
| Z23 | Encounter for immunization |
| 0-9 | A-Z |
|---|---|
| Z23 | Encounter for immunization |
Formulary Reference Tool